RT 100

Drug Profile

RT 100

Alternative Names: Ad5.hAC6; Adenylate cyclase gene therapy - Renova; RT100

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Renova Therapeutics
  • Class Gene therapies
  • Mechanism of Action Adenylate cyclase expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Heart failure

Most Recent Events

  • 08 Sep 2017 9222385 - updated intro, KDM, dev table and HE (As per the company's' pipeline, the overview section states that the the trial is planned in sec hf while the pipeline states as phase III, hence advanced the dev line)
  • 08 Sep 2017 Phase-III clinical trials in Heart failure in USA (Intracoronary) (Renova Therapeutics pipeline, September 2017)
  • 04 Aug 2017 RT 100 is still in phase II development for Heart failure in USA (Renova Therapeutics, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top